{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Angiogenesis",
    "query": {
      "condition": "Angiogenesis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 242,
    "total_pages": 25,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Angiogenesis&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T18:04:25.217Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00747305",
      "title": "Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "sunitinib malate",
          "type": "DRUG"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "reverse transcriptase-polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "western blotting",
          "type": "GENETIC"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "neoadjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Harry Drabkin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 17,
      "start_date": "2008-10",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2015-10-22",
      "last_synced_at": "2026-07-22T18:04:25.217Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00747305"
    },
    {
      "nct_id": "NCT00807859",
      "title": "Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Neoplasms",
        "Breast Tumors",
        "Cancer",
        "Locally Recurrent and Metastatic Breast Cancer",
        "Metastases",
        "Metastatic Cancer",
        "Oncology",
        "Solid Tumors",
        "Tumors"
      ],
      "interventions": [
        {
          "name": "AMG 386 30 mg/kg, Paclitaxel and Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "AMG 386 30 mg/kg, Capecitabine and Lapatinib",
          "type": "DRUG"
        },
        {
          "name": "AMG 386 10 mgkg, Paclitaxel and Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "AMG 386 10 mg/kg, Capecitabine and Lapatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 65,
      "start_date": "2009-03-09",
      "completion_date": "2015-10-19",
      "has_results": false,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-07-22T18:04:25.217Z",
      "location_count": 13,
      "location_summary": "Tucson, Arizona • Boca Raton, Florida • Iowa City, Iowa + 9 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00807859"
    },
    {
      "nct_id": "NCT04941274",
      "title": "Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Kaposi Sarcoma"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 111,
      "start_date": "2021-09-29",
      "completion_date": "2028-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-07-22T18:04:25.217Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04941274"
    },
    {
      "nct_id": "NCT02443324",
      "title": "A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastric Adenocarcinoma",
        "Adenocarcinoma of the Gastroesophageal Junction",
        "Non-small Cell Lung Cancer",
        "Carcinoma, Transitional Cell",
        "Biliary Tract Cancer"
      ],
      "interventions": [
        {
          "name": "Ramucirumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2015-07-29",
      "completion_date": "2022-04-12",
      "has_results": true,
      "last_update_posted_date": "2024-07-31",
      "last_synced_at": "2026-07-22T18:04:25.217Z",
      "location_count": 7,
      "location_summary": "New Haven, Connecticut • Fort Myers, Florida • St. Petersburg, Florida + 3 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02443324"
    },
    {
      "nct_id": "NCT01582685",
      "title": "Exercise in Breast Cancer Survivors",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Mississippi Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2012-04",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-12-02",
      "last_synced_at": "2026-07-22T18:04:25.217Z",
      "location_count": 1,
      "location_summary": "Jackson, Mississippi",
      "locations": [
        {
          "city": "Jackson",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01582685"
    },
    {
      "nct_id": "NCT00923117",
      "title": "Sunitinib to Treat Recurrent Brain Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Malignant Gliomas",
        "Anaplastic Gliomas"
      ],
      "interventions": [
        {
          "name": "Sutent (sunitinib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2008-06",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2015-09-30",
      "last_synced_at": "2026-07-22T18:04:25.217Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00923117"
    },
    {
      "nct_id": "NCT00574275",
      "title": "Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Neoplasm"
      ],
      "interventions": [
        {
          "name": "Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 546,
      "start_date": "2007-12",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2016-06-07",
      "last_synced_at": "2026-07-22T18:04:25.217Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00574275"
    },
    {
      "nct_id": "NCT01943916",
      "title": "The PIONEER-01 Study of the Imagio Breast Imaging System",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Imagio OA/US (US and OA/US)",
          "type": "DEVICE"
        },
        {
          "name": "Imagio gray scale ultrasound",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Seno Medical Instruments Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 2105,
      "start_date": "2012-12-21",
      "completion_date": "2015-09-09",
      "has_results": true,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-07-22T18:04:25.217Z",
      "location_count": 16,
      "location_summary": "Murrieta, California • Englewood, Colorado • New Haven, Connecticut + 13 more",
      "locations": [
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01943916"
    },
    {
      "nct_id": "NCT01753713",
      "title": "Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Recurrent Adult Brain Tumor"
      ],
      "interventions": [
        {
          "name": "dovitinib",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Manmeet Ahluwalia, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2012-12-20",
      "completion_date": "2017-09-20",
      "has_results": true,
      "last_update_posted_date": "2017-12-12",
      "last_synced_at": "2026-07-22T18:04:25.217Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01753713"
    },
    {
      "nct_id": "NCT00856180",
      "title": "Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Peritoneal Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2009-02",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2018-09-10",
      "last_synced_at": "2026-07-22T18:04:25.217Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00856180"
    }
  ]
}